Early Erythropoietin Administration does not Increase the Risk of Retinopathy in Preterm Infants

doi:10.1016/j.pedneo.2016.03.006

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 生活保健科技系 > 期刊論文 > Item 310902800/31751

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31751

標題:	Early Erythropoietin Administration does not Increase the Risk of Retinopathy in Preterm Infants
作者:	Chou, Hsin-Hsu Chung, Mei-Yung Zhou, Xiao-Guang Lin, Hung-Chih
貢獻者:	Ditmanson Med Fdn,Chia Yi Christian Hosp, Dept Pediat Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth Chang Gung Univ, Coll Med Nanjing Med Univ, Nanjing Childrens Hosp China Med Univ, Childrens Hosp China Med Univ, Sch Chinese Med
關鍵字:	erythropoietin meta-analysis retinopathy of prematurity
日期:	2017-02
上傳時間:	2018-11-30 15:55:20 (UTC+8)
出版者:	Elsevier Taiwan
摘要:	BACKGROUND: Erythropoietin (EPO) administration prevents anemia of prematurity and may be associated with a significant increase in the risk of retinopathy of prematurity (ROP) in preterm infants. Nonetheless, early EPO treatment may prevent damage following retinal neovascularization. The aim of this meta-analysis was to elucidate whether EPO administration increases the risk of ROP. METHODS: We searched MEDLINE, PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature), and the Cochrane Central Register of Controlled Trials with no language restrictions. Randomized controlled trials that reported the association between EPO treatment in preterm infants and ROP were eligible. All of the included studies were stratified into two groups according to the age of initiation of EPO treatment: before 8 days of age (early EPO), and 8-28 days of age (late EPO). RESULTS: Thirteen studies were identified that included a total of 1999 preterm infants. EPO administration did not increase the risk of ROP of any stage or Stage >= 3 (any relative risk: 0.99, 95% confidence interval: 0.84-1.16, p = 0.89; Stage >= 3 relative risk: 1.34, 95% confidence interval: 0.90-1.99, p = 0.15). This trend remained unchanged in both the early and late EPO groups. There did not seem to be any evidence of publication bias for outcomes as the funnel plots were symmetrical. CONCLUSION: EPO administration did not significantly increase the risk of ROP of any stage reported or Stage >= 3. Further clinical trials investigating the impact of EPO on ROP in premature infants should include all confounding factors to clarify this important issue. Copyright (c) 2016. Published by Elsevier B.V.
關聯:	Pediatrics and Neonatology, v.58, n.1, pp.48-56
显示于类别:	[生活保健科技系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	1425	检视/开启
j.pedneo.2016.03.006.pdf		1129Kb	Adobe PDF	0	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....